Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

NCT04833855 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

183

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria

Interventions

BIOLOGICAL: Tezepelumab Dose 1
BIOLOGICAL: Tezepelumab Dose 2
BIOLOGICAL: Omalizumab
BIOLOGICAL: Placebo

Sponsor

Amgen